Literature DB >> 25685752

Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome.

Benjamin F Chu1, Arwa Shana'ah2, Craig C Hofmeister1, Don M Benson1, Megan Sell1, Jill Tucker1, Flavia Pichiorri1, Yvonne A Efebera1.   

Abstract

Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines. The use of lenalidomide in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein with plasma cells, skin changes) has been reported, but its benefit in long-term use is not well established. A 55-year-old man with POEMS and debilitating polyneuropathy was treated with lenalidomide and dexamethasone followed by maintenance lenalidomide. He remains in haematologic remission and in complete recovery of functional status 3.5 years after diagnosis. This case supports the long-term use of lenalidomide in patients with POEMS syndrome.

Entities:  

Keywords:  Lenalidomide; POEMS

Year:  2014        PMID: 25685752      PMCID: PMC4326104          DOI: 10.12890/2014_000093

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  9 in total

1.  POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.

Authors:  José F Tomás; Pilar Giraldo; Ramón Lecumberri; Sara Nistal
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

2.  Lenalidomide therapy in a patient with POEMS syndrome.

Authors:  Angela Dispenzieri; Christopher J Klein; Michelle L Mauermann
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

3.  Successful bortezomib-based treatment in POEMS syndrome.

Authors:  Xiaowen Tang; Xiaolan Shi; Aining Sun; Huiying Qiu; Bin Gu; Huifen Zhou; Shengli Xue; Yuejun Liu; Changgeng Ruan; Depei Wu
Journal:  Eur J Haematol       Date:  2009-08-06       Impact factor: 2.997

4.  POEMS syndrome: update on diagnosis, risk-stratification, and management.

Authors:  Angela Dispenzieri
Journal:  Am J Hematol       Date:  2012-08       Impact factor: 10.047

5.  Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience.

Authors:  Anita D'Souza; Martha Lacy; Morie Gertz; Shaji Kumar; Francis Buadi; Suzanne Hayman; David Dingli; Steven Zeldenrust; Robert Kyle; Stephen Ansell; David Inwards; Patrick Johnston; Ivana Micallef; Luis Porrata; Mark Litzow; Dennis Gastineau; William Hogan; Angela Dispenzieri
Journal:  Blood       Date:  2012-05-18       Impact factor: 22.113

Review 6.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature.

Authors:  P A Bardwick; N J Zvaifler; G N Gill; D Newman; G D Greenway; D L Resnick
Journal:  Medicine (Baltimore)       Date:  1980-07       Impact factor: 1.889

Review 8.  New advances in the diagnosis and treatment of POEMS syndrome.

Authors:  Jian Li; Dao-bin Zhou
Journal:  Br J Haematol       Date:  2013-02-08       Impact factor: 6.998

9.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

  9 in total
  2 in total

1.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

2.  Kennedy Disease Misdiagnosed as Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report.

Authors:  Min Yuan; Weiping Chen; Huangyan Zhou; Zhilong Xiao; Wei Wang; Weidong Wang; Xiaoping Yin; Lijun Xu
Journal:  Med Princ Pract       Date:  2015-11-30       Impact factor: 1.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.